Renovaro (RENB) Competitors $0.72 -0.02 (-2.67%) Closing price 04:00 PM EasternExtended Trading$0.72 0.00 (-0.06%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RENB vs. ORKA, MGTX, PRTC, MREO, AKBA, ALT, KALV, PROK, KROS, and SAGEShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Oruka Therapeutics (ORKA), MeiraGTx (MGTX), PureTech Health (PRTC), Mereo BioPharma Group (MREO), Akebia Therapeutics (AKBA), Altimmune (ALT), KalVista Pharmaceuticals (KALV), ProKidney (PROK), Keros Therapeutics (KROS), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Oruka Therapeutics MeiraGTx PureTech Health Mereo BioPharma Group Akebia Therapeutics Altimmune KalVista Pharmaceuticals ProKidney Keros Therapeutics Sage Therapeutics Renovaro (NASDAQ:RENB) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is RENB or ORKA more profitable? Oruka Therapeutics' return on equity of -24.96% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -67.54% -52.89% Oruka Therapeutics N/A -24.96%-21.22% Which has higher valuation and earnings, RENB or ORKA? Oruka Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$80.65M-$0.96-0.75Oruka TherapeuticsN/AN/A-$5.34M-$6.26-1.90 Which has more volatility & risk, RENB or ORKA? Renovaro has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Does the MarketBeat Community favor RENB or ORKA? Oruka Therapeutics received 16 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformRenovaroN/AN/AOruka TherapeuticsOutperform Votes16100.00% Underperform VotesNo Votes Do analysts rate RENB or ORKA? Oruka Therapeutics has a consensus target price of $39.86, indicating a potential upside of 235.78%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media refer more to RENB or ORKA? In the previous week, Oruka Therapeutics had 6 more articles in the media than Renovaro. MarketBeat recorded 6 mentions for Oruka Therapeutics and 0 mentions for Renovaro. Renovaro's average media sentiment score of 1.89 beat Oruka Therapeutics' score of 0.53 indicating that Renovaro is being referred to more favorably in the media. Company Overall Sentiment Renovaro Very Positive Oruka Therapeutics Positive Do institutionals and insiders believe in RENB or ORKA? 71.4% of Renovaro shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 21.7% of Renovaro shares are held by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryOruka Therapeutics beats Renovaro on 11 of the 15 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.02M$6.89B$5.67B$9.04BDividend YieldN/A2.90%5.31%4.00%P/E Ratio-0.759.6390.3619.28Price / SalesN/A312.491,035.8379.86Price / CashN/A75.4646.0938.87Price / Book0.815.535.135.00Net Income-$80.65M$123.50M$113.24M$222.75M7 Day Performance-1.20%-4.00%-0.99%-0.57%1 Month Performance-9.34%-1.51%4.19%3.00%1 Year Performance-78.62%2.27%21.68%17.85% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro0.9317 of 5 stars$0.72-2.7%N/A-78.4%$114.02MN/A-0.7520Positive NewsORKAOruka Therapeutics2.6331 of 5 stars$13.70+1.9%$43.17+215.1%N/A$479.50MN/A-2.19N/AGap UpMGTXMeiraGTx4.7119 of 5 stars$6.13-2.5%$23.50+283.4%-2.0%$479.08M$13.93M-5.07300Positive NewsPRTCPureTech Health2.5599 of 5 stars$19.50+2.1%$45.00+130.8%-23.4%$466.83M$3.33M0.00100Positive NewsMREOMereo BioPharma Group2.8039 of 5 stars$2.99-0.7%$7.83+162.0%-27.5%$463.89M$1M0.0040News CoverageAKBAAkebia Therapeutics4.2116 of 5 stars$2.12-5.4%$7.50+253.8%+28.0%$462.54M$194.62M-9.22430Analyst UpgradeShort Interest ↓Gap DownALTAltimmune2.4555 of 5 stars$6.44-3.0%$20.83+223.5%-39.8%$458.05M$52,000.00-4.1550Short Interest ↓Gap DownKALVKalVista Pharmaceuticals4.7013 of 5 stars$9.22+3.5%$23.80+158.1%-42.1%$455.65MN/A-2.53100Insider TradeShort Interest ↓News CoveragePROKProKidney1.9141 of 5 stars$1.55-6.1%$4.50+190.3%+27.0%$452.07MN/A-2.823Positive NewsKROSKeros Therapeutics3.4433 of 5 stars$11.13-2.4%$52.56+372.2%-80.8%$450.84M$651,000.00-2.14100Short Interest ↑Analyst RevisionSAGESage Therapeutics4.6145 of 5 stars$7.26+0.1%$10.53+45.0%-69.6%$444.09M$86.46M-1.30690Earnings ReportAnalyst ForecastShort Interest ↓News Coverage Related Companies and Tools Related Companies Oruka Therapeutics Alternatives MeiraGTx Alternatives PureTech Health Alternatives Mereo BioPharma Group Alternatives Akebia Therapeutics Alternatives Altimmune Alternatives KalVista Pharmaceuticals Alternatives ProKidney Alternatives Keros Therapeutics Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RENB) was last updated on 2/12/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored New Options "Trading GPS" = 91% Win-RateThink of it as GPS navigation for the options market... Even traders who previously found options "too comp...Eagle Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the cl...Colonial Metals | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.